Work

Co-Clinical Trials Demonstrate Superiority of Crizotinib to Chemotherapy in ALK-Rearranged Non-Small Cell Lung Cancer and Predict Strategies to Overcome Resistance

Year: 2020

Type: article

Abstract: To extend the results of a phase III trial in non-small cell lung cancer patients with adenocarcinomas harboring EML4-ALK fusion.

Source: Carolina Digital Repository (University of North Carolina at Chapel Hill)

DOI: 10.17615/b6ha-gp80

Authors: Engelman, Jeffrey A., Tupper, Tanya, Chen, Liang, Kung, Andrew L., Wong, Kwok Kin, Cheng, Katherine, Akbay, Esra, Janne, Pasi A., Woo, Sue Ann, Altabef, Abigail, Reibel, Jacob B., Mikse, Oliver, Wang, Yuchuan, Shapiro, Geoffrey I., Sharpless, Norman E., Chen, Zhao, Tan, Xiaohong

Institution: University of North Carolina at Chapel Hill

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: AstraZeneca, Takeda Oncology

OpenAlex ID: W4298523681

FWCI: 0.369

Cites:

Cited by: 5

Related to: 10